The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Subscribe To Our Newsletter & Stay Updated
